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The care and treatment of spinal cord injury (SCI) patients has significantly evolved 
over the last several decades. There has been great interest and promising research 
conducted over this period resulting in advancement of our understanding of the 
pathophysiology of SCI on both a biochemical and biomolecular level. Concur-
rently, there has also been rapid clinical advancements in treating spinal fractures 
with improvement in the understanding of the biomechanics of injuries, as well as 
improvements in spinal fixation techniques and devices. In addition, there have been 
great strides made in the collaborative care and treatment efforts of SCI patients 
particularly in the fields of radiology, rehabilitation, trauma, and intensive care.
The developments in SCI treatment have led to a decrease in the overall incidence 
of traumatic injuries, particularly in the younger populations. This is mainly a result 
of preventative measures and education by the various foundations who focus on 
the treatment of SCI patients such as CSRS, ASIA, AAOS, CNS, and AANS. In addition, 
there has been a greater emphasis in society on limiting catastrophic injuries such as 
through the use of: airbag immobilization in motor vehicles, helmets, and the overall 
reduction of high-risk activities.
To provide some background information on the pathophysiology of a traumatic SCI, 
it is believed that SCI is multifaceted, with the initial force or compression of the cord 
resulting in the primary injury. This is then followed by an inflammatory or biochemical 
response that results in further injury to the cord over the subsequent days to weeks. 
This is referred to as the secondary injury, and it is this stage of injury that has been the 
target of intense research. Currently, there exists multiple novel strategies in dealing with 
this secondary injury component including surgical techniques, medical management, 
pharmacology, and cell-based therapies which will be discussed below.
SURGICAL TECHNIQUES
Over the last century, it is been established that early decompression of the spinal 
cord results in improved neurologic outcomes. However, not until the publication of 
the STASCIS study (PLoSOne. 2013 Aug 23;8(8):e72659) has clinical data significantly 
demonstrated that early decompression does, indeed, improve neurological outcome. 
This study, in which Jefferson Health was the highest enrolled center, showed that 
surgical decompression and stabilization in less than 24 hours gave the patient the 
greatest chance of improving by up to two neurologic grades in the ASIA scale.
Another area of exciting research has been the use of a biocompatible scaffold poly-
mers for acute spinal cord injury, which is also an option for patients at Jefferson 
Health. This scaffold is surgically inserted into the spinal cord at the site of injury and 
will break down over several weeks. It is postulated that this polymer modulates the 
healing environment in acute injury and provides the structural support in both acute 
and chronic injury necessary to promote a local environment supportive of cell survival 
and growth within the spinal cord. The INSPIRE trial, a study from InVivo therapeutics 
(http://www.invivotherapeutics.com) examined the potential benefit of this Neuro-
Spinal Scaffold (TM) for safety and neurologic recovery in patients with complete 
thoracic (T2-T12) spinal cord injury. This 
study is currently being analyzed and 
there appears to be a neurologic benefit 
with use of this polymer scaffold. Larger 
and more comprehensive studies will 
likely take place following final analysis 
of the data from this trial. 
MEDICAL MANAGEMENT
The medical intensive care treatment of 
the patients after their traumatic SCI is also 
extremely important in overall recovery 
and prognosis. It has been determined 
throughout the last several decades that 
increased blood flow to the spinal cord 
by maintaining patients with an elevated 
mean arterial pressure significantly 
improves neurologic recovery. This is 
akin to elevating the blood pressure in an 
acute stroke patient so as to perfuse the 
brain penumbra that has not yet reached 
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Figure 1.
Sagittal T2-weighted MRI demonstrating 
post spinal cord injury with increased 
signal and edema within the cervical 
cord (arrow) along with superimposed 
cervical stenosis
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oligodendrocytes, which function to 
provide support and myelin production 
in the central nervous system.
In another trial, named the StemCell Inc 
trial, HuCNS stem cells were implanted 
through direct spinal cord parenchymal 
injections within one year of the injury. 
Despite showing promising improvements 
in neurologic recovery, the study was 
unfortunately halted due to financial issues.
Currently, there is an active trial investi-
gating the use of Schwann cell transplants 
being performed at the University of 
Miami. This study uses Schwann cells 
harvested from the patient and transfers 
them directly into spinal cord injury site. 
The results of the phase 1 portion of this 
trial were published in 2017 and showed 
the safety of this treatment, noting that 
there were no adverse events or serious 
adverse events related to the cell therapy.
It is important to realize, however, that 
that with any new treatment, there can 
be significant complications. Particularly 
related to cell-based therapies, such as 
implantation of stem cells, there is the 
possibility for inducing aberrant growth of 
non-spinal cord tissue which has potential 
to harm the surrounding neural structures.
by blocking the rho activation system. In 
the initial phase 1 study, which compared 
the medication to case controls, not 
only was the medication safe, but it also 
showed to be efficacy. Unfortunately, 
when the medication was compared 
to placebo there was no significant 
improvement, so the trial was ultimately 
halted. However, the study did result in 
greater interest in the investigation of 
drugs to treat and modulate injuries to 
the spinal cord.
CELL-BASED THERAPIES
There is a good deal of excitement about 
the possibility of cell mediated interven-
tions being used to improve neurologic 
outcomes after SCI. We are very fortu-
nate at Jefferson to have been asked to 
participate in many studies investigating 
this topic and strategy. The first stem cell 
spinal cord injury trials were performed 
by Geron Corporation, although, they 
were eventually halted and sold to 
a secondary company that became 
known as Asterias (https://asteriasbio-
therapeutics.com). Asterias has been a 
proponent of intraparenchymal spinal 
cord injection of stem cells. Unlike some 
other cell-based strategies, these do not 
target the neurons directly but rather the 
terminal ischemia. In addition, there is 
interest in the use of hypothermia to 
decrease the metabolic bands of the spinal 
cord during the acute phase of injury to 
help aid in recovery. Jefferson is currently 
involved in this study through a grant from 
the Department of Defense.
PHARMACOLOGY
The largest international SCI pharma-
cological multicentered prospective 
randomized controlled study is presently 
being run through the AO Foundation. 
Jefferson is currently the largest clinical 
enrolling site in North America. This study 
is investigating the drug, Riluzole, which 
is approved for patients with ALS, and its 
effect on reducing excitatory apoptosis 
(cell-initiated death) after an injury to the 
spinal cord. This is a continuation of a 
phase 1 study, also done at Jefferson, 
which showed safety of the medication.
Unfortunately, not all promising initial 
studies are confirmed during their phase 
3 trials. Recently, Jefferson was involved 
with the Vertex SCI trial which examined 
a medication to prevent cell apoptosis 
Figure 3.
(Left) Sagittal T2-weighted MRI and (Right) CT scan demonstrating a thoracic flexion-
distraction injury (fracture dislocation) causing severe spinal cord compression
Figure 2.
Intraoperative lateral radiograph 
demonstrating post-surgical instrumented 
posterior cervical fusion hardware
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Although the overall incidence of 
spinal cord injury is decreasing in our 
population, it is still a major public 
health concern. The costs associated 
with treating and caring for patients 
with spinal cord injuries is quite signifi-
cant. Currently, there is no “cure” that 
exists which allows the spinal cord to 
regenerate and heal completely after a 
traumatic injury, making many of these 
injuries devastating to the patients 
and their families. However, with 
advancements in surgical, medical, and 
pharmacological research coming to 
fruition at a rapid pace, the outlook on 
evolving the care of these patients and 
their injuries is promising.
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